# Exploring Peptides for Low Libido and HSDD: Clinical Insights and Anecdotal Reports

Canonical source: https://retacompare.com/research/top-peptides-studied-or-used-for-low-libido-hsdd

Peptides for Disease — Top Peptides · 2026-05-03


    This article reviews peptides studied for low libido and HSDD, highlighting Bremelanotide as the only FDA-approved option for women, alongside emerging candidates and anecdotal uses in the community. Understanding the distinction between clinical evidence and self-reported experiences is essential.


The big picture

Low libido, or hypoactive sexual desire disorder (HSDD), affects many individuals, particularly premenopausal women. It can significantly impact quality of life and interpersonal relationships. Various treatment options exist, including pharmacological interventions. Among these, peptides have gained attention for their potential effects on sexual desire and arousal. This article focuses on peptides that are either FDA-approved, in clinical trials, or used anecdotally within biohacker communities for low libido and HSDD. For broader context, see the broader research library and our peptide stacking guide.


What the clinical evidence shows

Currently, the only FDA-approved peptide for HSDD is Bremelanotide (Vyleesi), specifically indicated for premenopausal women. Bremelanotide is a melanocortin receptor agonist that has been shown to enhance sexual desire. Clinical studies have demonstrated its efficacy in improving sexual desire in women with HSDD, with a favorable safety profile. Other peptides, such as PT-141 (Bremelanotide's active component), have also been explored for off-label use in men, though they lack formal approval for this indication. Other peptide candidates, such as Selank and Semax, have been studied for their anxiolytic and cognitive-enhancing properties, which may indirectly influence sexual health, but they are not FDA-approved for low libido or HSDD.


What the community reports anecdotally

Anecdotal reports from biohacker communities suggest that various peptides, including PT-141 and Ipamorelin, are being experimented with for enhancing libido in both men and women. Users report positive experiences, claiming improvements in sexual desire and performance. However, it is crucial to note that these reports are self-reported and lack controlled clinical trials to substantiate their claims. Many individuals share their experiences on forums and podcasts, discussing dosages and effects, but these findings should be approached with caution due to the absence of rigorous scientific validation.


Key points at a glance

Bremelanotide is the only FDA-approved peptide for HSDD in premenopausal women.

Other peptides like PT-141 are used off-label and lack formal approval for low libido in men.

Anecdotal reports suggest various peptides may enhance libido, but these claims are not clinically validated.

Peptides such as Selank and Semax are explored for their potential effects on mood and cognition.

Community discussions often lack scientific rigor, emphasizing the need for caution.


Safety and what to watch for

While some peptides may offer potential benefits, their safety profiles can vary. Bremelanotide, for example, has been associated with side effects such as nausea and headaches. Off-label use of peptides like PT-141 and Ipamorelin can pose risks due to unregulated dosages and lack of quality control. Users should be aware of potential side effects and contraindications, and it is advisable to consult healthcare professionals before considering peptide therapies.


Open questions

Significant gaps remain in the understanding of peptides for low libido and HSDD. Future research is needed to establish the efficacy and safety of many peptides currently used in the community. Regulatory approval processes for new peptide therapies can be lengthy, and the landscape of approved treatments may evolve as more data becomes available. Researchers are investigating the mechanisms by which these peptides may influence sexual desire, which could lead to new therapeutic options.


Bottom line

While Bremelanotide remains the only FDA-approved peptide for HSDD, other peptides are being explored both clinically and anecdotally. Caution is warranted, as many peptides discussed in the community lack formal approval and clinical validation.


This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Low Libido / HSDD or any indication. Do not start or change therapy without consulting a qualified clinician.

## Sources